FDA

FDA Has Approved The Anti-Alzheimer’s Drug Leqembi. What You Need To Know

The Food and Drug Administration (FDA) has granted final approval to the anti-Alzheimer’s drug lecanamab, marked as Leqembi by drugmakers Eisai and Biogen. Here is what you need to know: What does it do? In a formal phase 3 trial, Leqembi was shown to slow the progression of memory loss and cognitive impairment in patients with early-stage Alzheimer’s disease by [...]

By |2023-07-06T17:25:34-04:00July 6th, 2023|dementia, Uncategorized|0 Comments

The Biggest Barrier To New Anti-Alzheimer’s Drugs May Be Cost, Not Medicare Rules

The drug industry and its supporters are blasting the Centers for Medicare and Medicaid Services (CMS) for proposing to limit Medicare payments for the new anti-Alzheimer’s drug lecanemab to patients who participate in a trial or a special registry aimed at tracking their experience with the drug. CMS says the record-keeping will help provide important, real-world information about the benefits [...]

By |2023-06-14T12:12:06-04:00June 14th, 2023|dementia|0 Comments

The War Over Whether Medicare Should Pay For New Anti-Alzheimer’s Drugs

The powerful Alzheimer’s Disease lobby is fighting a multi-billion-dollar battle on two fronts. It is quietly trying to limit restrictions the Food and Drug Administration puts on the use of new drugs aimed at slowing the progression of the brain disease. And it is publicly pressing Medicare to pay for the widespread use of the monoclonal antibodies FDA already has [...]

By |2023-05-17T15:27:50-04:00May 17th, 2023|dementia|0 Comments

Experts Raise New Questions About The Safety Of Anti-Alzheimer’s Drug Leqembi

Medical experts are raising new questions about the safety of the anti-Alzheimer’s drug lecanemab, which is marketed as Leqembi by drugmakers Biogen and Eisai. One study, which looked in detail at the death of a participant in a Leqembi research trial, suggests that people with a condition that affects as many as half of those with Alzheimer’s Disease may be [...]

By |2023-04-25T10:22:43-04:00April 25th, 2023|dementia|0 Comments

The FDA Approved The New Anti-Alzheimer’s Drug Leqembi. What You Need To Know

The FDA’s decision to grant accelerated approval for the anti-Alzheimer’s drug lecanemab, which will be sold as Leqembi, has significant potential for research into treatment of the disease. But people living with Alzheimer’s and their families will face difficult choices once the drug is made available later this month by Biogen and the Japanese firm Eisai. A trial found the [...]

By |2023-01-09T09:58:28-05:00January 9th, 2023|dementia, Uncategorized|0 Comments

FDA Upends The Hearing Aid Market By Permitting Sales Of Non-Prescription Devices

After years of internal debate, the FDA has approved the sale of over-the-counter hearing aids. The move will make the devices available to consumers with mild to moderate hearing loss as soon as mid-October. The move not only could save a typical buyer several thousand dollars, it also opens the door to potential new technologies that could improve the quality [...]

By |2022-08-16T14:53:39-04:00August 16th, 2022|Health Care|0 Comments

Medicare Won’t Pay for Controversial Alzheimer’s Drug Aduhelm Without A New Trial

In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial. In bureaucratic language: “Monoclonal antibodies directed against amyloid for the treatment of [Alzheimer’s Disease] provided outside of the CMS approved randomized controlled trials and trials supported [...]

By |2022-01-11T17:46:04-05:00January 11th, 2022|dementia|0 Comments

What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?

This week, drugmaker Biogen made a stunning announcement: It is going to cut in half the price of its controversial Alzheimer’s drug Aduhelm. Instead of selling the infusion drug for $56,000 annually to a typical user it will charge $28,000-a-year. It is, to say the least, unusual, for the maker of a potential blockbuster drug to cuts its price just [...]

By |2021-12-23T14:28:34-05:00December 23rd, 2021|dementia|0 Comments

With Medicare Undecided On Whether To Pay, Alzheimer’s Drug Maker Biogen Offers Free Doses

A funny thing happened on the way to that $56,00-a-year Alzheimer’s drug: Payers are reluctant to pay, providers are reluctant to prescribe, and the price is coming down—at least for some patients. It is a tale  that could push Congress to allow Medicare to negotiate drug prices. Reuters reports that Biogen, which sells the controversial medication it calls Aduhelm, is [...]

By |2021-09-01T15:11:40-04:00September 1st, 2021|dementia|0 Comments

Will Medicare Pay For The New Alzheimer’s Drug?

Last month, The Food and Drug Administration (FDA) approved a controversial new drug to treat people with Alzheimer’s disease. But even though the FDA allowed the drug to be sold, Medicare is not required to pay for it. And yesterday, the Centers for Medicare & Medicaid Services (CMS) began a process to determine whether Medicare will establish a national coverage [...]

By |2021-07-13T13:57:06-04:00July 13th, 2021|dementia|0 Comments